Yazar "Ozdemir, Ozgur" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ N/A ]
    Öğe
    Comparison of the efficacy and adverse effects of trospium chloride and tolterodine tartrate in the treatment of overactive bladder symptoms
    (Galenos Yayincilik, 2008) Guven, Melih Atahan; Coskun, Ayhan; Gungoren, Arif; Ozdemir, Ozgur; Ercan, Onder; Karakus, Savas
    Objective: To compare the efficacy and adverse effects of two antimuscarinic agents (trospium chloride (TCl), tolterodine Ltartrate) in patients having overactive bladder symptoms. Material and Method: During 2005, patients admitted with urge incontinence to Faculty of Medicine, Gynaecology Clinic and answered overactive bladder evaluation questionnaire form, and given Tolterodine-L-Tartrate (Detrusitol (R)) 2 mg, 2x1 (n: 38), Trospium chloride (Spazmex (R)) 30 mg tb 2x1 (n: 41), were retrospectively evaluated. Patients taken both drugs were determined by giving points regarding efficacy and adverse effects as questioned in the questionnaire form at the 1st and 3rd months following the initiation of treatment. Results: Demografic data were similar in both groups (p> 0.05). Points given after treatment were found significantly lower than the points given before treatment in both groups (p<0.001). The efficacy and adverse effects of both drugs were found statisticaly similar (p>0.05). Conclusion: In the highligths of retrospevtive data, we concluded that Trospium chloride and Tolterodine may be used alternatively to each other in treatment of overactive bladder.
  • Küçük Resim
    Öğe
    Protective and therapeutic effects of nobiletin against cisplatin-induced nephrotoxicity in rats
    (Taylor & Francis Ltd, 2024) Kazak, Filiz; Coskun, Pinar; Yarim, Gul Fatma; Baspinar, Nuri; Ozdemir, Ozgur; Ates, Mehmet Burak; Altug, Muhammed Enes
    Possible protective and therapeutic effects of nobiletin on kidney in a cisplatin-induced nephrotoxicity rat model were investigated. Forty male albino rats were divided into four groups: control, cisplatin (CIS), cisplatin+nobiletin (CIS+NOB), and nobiletin+cisplatin (NOB+CIS). At the end of the study, the rats were subjected to biochemical, histological and immunohistochemical analyzes. Compared to the control group, tGSH (p < 0.05) levels, and G6PD (p < 0.05) and GPx (p < 0.001) activities, were increased in the CIS group; while significant (p < 0.05) decreases occurred in the MDA and TOC levels. Histopathologically, the kidneys of the groups administered nobiletin (CIS+NOB, NOB+CIS) were significantly different from the CIS group, being closer to control group in terms of degeneration and hyaline cylinder formation in the tubules (p < 0.05). While dilatation in the tubules, protein-rich fluid and hyaline cylinder formation in the lumen were most common in the CIS group, a significant decrease (p < 0.05) of these parameters was seen in the nobiletin groups (CIS+NOB, NOB+CIS). This study suggests that nobiletin can be effective in preventing and ameliorating toxic effects of cisplatin on the kidney.
  • Küçük Resim
    Öğe
    Protective effects of nobiletin on cisplatin induced neurotoxicity in rats
    (Taylor & Francis Ltd, 2022) Kazak, Filiz; Akalin, Pinar Peker; Yarim, Gul Fatma; Baspinar, Nuri; Ozdemir, Ozgur; Ates, Mehmet Burak; Altug, Muhammed Enes
    Objectives This study was designed to investigate the possible antioxidant, antiapoptotic and neuroprotective effects of nobiletin on cisplatin-induced neurotoxicity rat model by evaluating neurotrophins, antioxidants and histopathology. Methods Forty male Wistar Albino rats were divided into four groups: control, cisplatin (CIS), cisplatin + nobiletin (CIS + NOB) and nobiletin + cisplatin (NOB + CIS). CIS + NOB was applied nobiletin (10 mg/kg, i.p.) during the last four days whereas NOB + CIS was applied nobiletin during the first four days of the study. Cisplatin (4 mg/kg, i.p. twice a day) was administered to the experimental groups on the 5th day of the study. All rats were sacrificed on the 10th day of the study. BDNF, NGF, G6PD, GPx, tGSH and MDA levels were determined in brain. In addition, routin histolopathological analysis and caspase-3 immunoreactivity assay were conducted. Results BDNF concentrations increased in nobiletin-administered groups, compared to Control and CIS and that the increase was statistically significant in NOB + CIS (p < 0.05). It was also found that G6PD activity increased (p < 0.05) in the nobiletin-administered groups, compared to control and CIS. Histopathologically, neuronal degeneration, oedema and gliosis increased in CIS compared to Control, and nobiletin administration decreased neuronal degeneration and oedema compared to CIS (p < 0.05). Cisplatin increased (p < 0.05) caspase-3 immunoreactivity in cerebrovascular endothelium and neurons compared to Control, while nobiletin administration decreased caspase-3 immunoreactivity in cerebrovascular endothelium. Caspase-3 immunoreactivity in neurons decreased only in NOB + CIS (p < 0.05). Conclusion Nobiletin increased BDNF concentration and G6PD activity in brain and when evaluated together with histopathological and immunohistochemical findings, it may have antioxidant, antiapoptotic and neuroprotective effects against cisplatin.